<DOC>
	<DOCNO>NCT02283515</DOCNO>
	<brief_summary>BACKGROUND : Chronic periodontitis ( CP ) inflammatory condition affect tooth support tissue alveolar bone surround tooth lead formation deepend gingival sulcus highly prone pathologic change , ultimately bone resorption tooth loss . In literature , several pharmacologic agent administration via local delivery route , directly diseased site affirm great improvement periodontal status . Therefore , present study conduct determine clinical effectiveness subgingivally deliver 1.2 % Rosuvastatin gel incorporate methylcellulose vehicle control release intrabony defect sit adjunct scale root plan treatment chronic periodontitis patient . MATERIAL AND METHODS : Sixty five patient categorize two treatment group : group I -SRP plus RSV , 1.2 mg group II -SRP plus placebo . Clinical parameter include modified sulcus bleed index ( mSBI ) , probe depth ( PD ) , clinical attachment level ( CAL ) , record baseline SRP 1 , 3 , 4 , 6 month . Radiologic assessment intrabony defect ( IBD ) fill analyse baseline 6months use computer-aided software .</brief_summary>
	<brief_title>Efficacy Locally Delivred 1.2 % Rosuvastatin Gel Chronic Periodontitis</brief_title>
	<detailed_description>Rosuvastatin ( RSV ) one new synthetic , second-generation , sulfur-containing , hydrophilic statin , highly efficient competitive inhibitor HMG CoA Reductase important role reduce serum cholesterol concentration lower risk cardiovascular disease . It potent anti-inflammatory effect , mediate via vascular endothelium derive nitric oxide ( eNO ) inhibit P selectin synthesis endothelial cell . This protective action evidence reduced level high-sensitivity C-Reactive Protein ( hs-CRP ) , clinical marker inflammation produce response proinflammatory cytokine interleukin-6 ( IL-6 ) , therefore contribute prevention remission inflammatory disease . Recently , in-vivo study demonstrate RSV promotes osteoblast differentiation , regulate expression solute carrier ( Slco1a1 ) , may constitute transport system RSV across cell membrane mature osteoblast . SRP plus RSV ( 1.2 mg/0.1 ml ) situ gel ( group I ) SRP plus placebo gel ( group II ) local drug delivery</detailed_description>
	<mesh_term>Periodontitis</mesh_term>
	<mesh_term>Chronic Periodontitis</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Systemically sound moderate probe depth ( PD ) 5 6 mm clinical attachment loss ( CAL ) 4 6 mm ) deep pocket ( PD ≥ 7 mm CAL 6 9 mm ) vertical bone loss ≥ 3 mm intraoral periapical radiograph . Subjects ≥ 20 teeth history periodontal therapy precede 6 month antibiotic therapy include study . Patients systemic statin therapy know suspect allergy RSV group , patient form periodontitis , use tobacoo form , smoker , alcoholic , immunecompromised systemically unhealthy patient , pregnant lactating female exclude .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>chronic periodontitis</keyword>
	<keyword>local drug delivery</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>osseo-differentiation</keyword>
</DOC>